EXCLUSIVE: Clearmind Medicine's Psychedelic-Based Treatment Shows Encouraging Preclinical Activity In Obesity, Metabolic Disorders
Portfolio Pulse from Vandana Singh
Clearmind Medicine Inc (NASDAQ:CMND) and SciSparc Ltd (NASDAQ:SPRC) have reported positive preclinical trial results for a combination therapy treating obesity and metabolic disorders. The therapy combines Clearmind's psychedelic MEAI and SciSparc's anti-inflammatory PEA. The trial found optimal dosages that increased metabolic processes and fat burn while reducing appetite and meal sizes without affecting animal viability. Clearmind also announced a 1-for-30 reverse share split effective today.
November 28, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearmind Medicine Inc announced positive preclinical trial results for its obesity and metabolic disorder treatment and a 1-for-30 reverse share split.
Positive trial results typically lead to increased investor interest and could raise the stock price. However, reverse stock splits are often viewed negatively as they can indicate a company's attempt to boost its share price artificially. The net impact could still be positive due to the promising trial results.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
SciSparc Ltd's proprietary ingredient PEA was part of the successful preclinical trial in combination with Clearmind's MEAI for treating obesity and metabolic disorders.
SciSparc's involvement in the successful trial could be seen as a positive development for the company, potentially leading to increased investor interest and a positive impact on the stock price in the short term.
CONFIDENCE 70
IMPORTANCE 70
RELEVANCE 70